{"id":"NCT00975143","sponsor":"Cipher Pharmaceuticals Inc.","briefTitle":"Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne","officialTitle":"A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2011-05","completion":"2011-05","firstPosted":"2009-09-11","resultsPosted":"2014-07-04","lastUpdate":"2014-07-04"},"enrollment":925,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Severe Nodular Acne"],"interventions":[{"type":"DRUG","name":"CIP-Isotretinoin","otherNames":[]},{"type":"DRUG","name":"Isotretinoin","otherNames":[]}],"arms":[{"label":"CIP-Isotretinoin","type":"EXPERIMENTAL"},{"label":"Isotretinoin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy and safety of CIP-Isotretinoin and a marketed (generic) formulation of isotretinoin when both are administered twice daily with meals.","primaryOutcome":{"measure":"Co-primary Outcome 1: Change From Baseline in Total Nodular Lesion Count (Facial and Truncal)","timeFrame":"20 weeks","effectByArm":[{"arm":"CIP-Isotretinoin","deltaMin":-17.01,"sd":14.26},{"arm":"Isotretinoin","deltaMin":-16.52,"sd":10.57}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5077"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":17},"locations":{"siteCount":49,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":464},"commonTop":["Lip dry","Dry skin","Back pain","Dry eye","Arthralgia"]}}